Question follow-through · 8938
Drugs: Side Effects
To ask the Secretary of State for Health and Social Care, what data his Department and the Medicines and Healthcare products Regulatory Agency holds on how many and what proportion of patients develop withdrawal symptoms, including dopamine agonist withdr
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 10 Jun 2026
- Target answer date
- 15 Jun 2026
- Answer
- 8 Jul 2026 · 28 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Drugs: Side Effects · 11 Jun 2026
- Drugs: Side Effects · 11 Jun 2026
- Drugs: Side Effects · 11 Jun 2026
- Drugs: Side Effects · 11 Jun 2026
- Drugs: Side Effects · 11 Jun 2026
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
10 Jun 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what data his Department and the Medicines and Healthcare products Regulatory Agency holds on how many and what proportion of patients develop withdrawal symptoms, including dopamine agonist withdr
15 Jun 2026
Target answer date
Date supplied by the official written-questions record.
8 Jul 2026
Answer published
The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential financial impact of dopamine agonist-related impulse control disorders on those experiencing such disorders, including through (a) gambling-
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of dopamine agonist-related impulse control disorders and augmentation in people with restless legs syndrome and Parkinson’s disease
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what data the Department holds on the number and proportion of dopamine agonist-treated patients with impulse control disorders who experience relationship breakdown or divorce.
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the level of suicides and attempted suicides among (a) people prescribed dopamine agonists who have experienced impulse control disorders, augmentation or
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices whe
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the levels of (a) sexually transmitted infections acquired in the context of dopamine agonist-induced hypersexuality and (b) unplanned pregnancies among w
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, whether his Department holds audit or research data on differences between neurology or movement disorder specialists and general practitioners in (a) warning patients and families about dopamine a
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effectiveness of how dopamine agonist-related impulse control disorders and augmentation are taught and assessed in undergraduate medical educat
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential do
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse cont
Drugs: Side Effects
11 Jun 2026 · To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonis